Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis

Summary

To assess the efficacy and safety of MEDI9929 in adult subjects with Atopic Dermatitis

Timeline

Start

2015-08-15

Primary completion

2016-05-09

Completion

2016-07-15

Outcome

Missed primary endpoint

registry analysis (superiority test); Placebo vs MEDI9929 280 mg; Odds Ratio (OR) 1.97 (95% CI 0.90 to 4.33) NCT02525094 ↗

Drugs

Indications